Landsteiner Genmed

Landsteiner Genmed (LGM) is a biotech company founded in 2013 that is built on the experience and know-how of private and public research teams with international recognition working on the selection, synthesis, and development of products for which there is a need to treat diseases.

To this end, LGM possesses a DNA database of patients with different pathologies which it has put to work to identify new therapeutic targets in order to test newly synthesized compounds. Currently LGM has an arsenal of more than 600 products available for testing against the aforementioned targets.

LGM is a value proposition for developing first-in-class medicines from an ever-expanding proprietary chemo-library of thousands of products designed to be tested on currently identified targets.

LGM’s development strategy ranges from early-stage chemical synthesis and hit finding to clinical proof of concept.

Through this process, LGM has obtained compounds with high added value in the treatment of a variety of diseases and pathological processes such as obesity, fibrosis, heart failure, Alzheimer’s disease and cancer.

We develop
pharmaceutical 
products

Mission

The main mission of Landsteiner Genmed (LGM) is to develop pharmaceutical products which modulate disease associated targets identified through genomic analysis. LGM focuses its activity on unmet medical needs.

LGM focuses its activity on unmet medical needs.

We look for
unmet medical
treatments

Vision

The Landsteiner Genmed vision is to achieve international recognition in the therapeutic fields of fibrosis, cardiac ischemia, metabolic diseases, neurodegenerative pathologies, and cancer, through scientific excellence.

And at the same time to develop new treatments that will allow us to reach agreements with pharma labs with internationally consolidated sales networks.

We work together with
national and international
research centers.

Organization

Landsteiner Genmed is a biotech company based in Seville, Spain, in affiliation with Landsteiner Scientific, an internationally recognized Mexican pharma company in the field of generic drugs in Latin America.

Even though all research activity is performed in public and private research centers, both national and international, the Seville headquarters is where all studies are organized and monitored in order to provide full support in the development of future drugs that to which the organization is committed.

Our team

Enrique Vázquez

CEO

Enrique Vázquez Tatay has a degree in pharmacy and a PhD in molecular and…

Enrique Vázquez Tatay has a degree in pharmacy and a PhD in molecular and cellular biotechnology from the University of Seville. In the year 2000 he obtained his masters in economics and business management at the San Telmo International Institute. He has co-founded various companies in the biotechnology sector. Furthermore, during the course of his business career he has received several awards for excellent business practice, innovation, and entrepreneurship, and he has been recognized in the field of creating new companies. Dr. Vázquez has had about 10 articles published in international journals and is jointly responsible for patents related to the search for treatments in complex illnesses. At the present time he is a founding partner and the general manager of Landsteiner Genmed.

LinkedIn
+

Evaristo Fernández

Administrative Head

Evaristo Fernández Aranda has a degree in economics and business management from…

Evaristo Fernández Aranda has a degree in economics and business management from the Complutense University of Madrid (UCM). He has a degree in law from The National Distance University (UNED) and an E-MBA from the San Telmo International Institute.

From the outset he has pursued a professional career in the private sector, in different parts of the business world, and in different company areas. His experience in managing companies started in the consulting process of large international multinationals and led to the business management of small biotechnological companies.

LinkedIn
+

Beatriz Cabrera

Administrative

Beatriz Cabrera del Olmo has a degree in fine arts from the University of Seville. She…

Beatriz Cabrera del Olmo has a degree in fine arts from the University of Seville. She completed post-graduate courses in the United Kingdom and Italy. Her career has developed in different sectors related to art, tourism, and design. She also possesses wide experience as an administrative assistant, as she has carried this responsibility in a number of companies in the private sector. She is bilingual in Spanish and English with proficiency in Italian and French. She has been part of our administrative team since 2013.

+

Andres G. Fernández

CSO

Dr Andrés Fernández holds an MPharm and a PhD degree in Pharmacology from the University of Barcelona and a PMD from ESADE Business School. He is a European Certified Pharmacologist (EuCP).

Dr Andrés Fernández holds an MPharm and a PhD degree in Pharmacology from the University of Barcelona and a PMD from ESADE Business School. He is a European Certified Pharmacologist (EuCP).
His previous positions include Director of Ferrer Advanced Biotherapeutics (Ferrer); Biotechnology and Biological Sciences, Director (Ferrer); Member of the Executive Board and R&D Director (Salvat Biotech); Associate Director of Drug Discovery (Almirall); Associate Professor Cell Biology (UAB); Head of Pharmacology (Almirall). Dr Fernandez has had direct executive and scientific responsibilities on teams successfully developing and launching: 6 New Molecular Entities (EU/USA/ASIA); 1 New Therapeutic Entity in USA/EU, and 1 New Molecular DX product in oncology in the EU.
He is active in creating NewCos and has participated as a Mentor in the valorization and pre-funding process of 5 spin-off companies currently invested by VC.
Dr Fernandez is the co-inventor of 12 granted international family patents. Member of the Board of the Spanish Pharmacological Society. Expert Panel Member and Mentor in CaixaResearch Programmes. Former Chairman of the Program Committee of the International Union of Pharmacology (IUPHAR). Former member of the Board of Directors of ASEBIO. Former President of the Catalan Society of Medical Biotechnology. Member of the Scientific Committee of multiple Congresses and Meetings. Member of the Jury of various Scientific Awards. Frequent Invited Speaker at Academic or Business events.

LinkedIn
+

Paul Beswick

Consulting team

Paul received a PhD in Organic Chemistry from Imperial College
(University of London)…

Paul received a PhD in Organic Chemistry from Imperial College (University of London) in 1984. After graduation he joined Glaxo as a medicinal chemist where he worked in a number of roles over 25 years and ultimately became Head of Medicinal Chemistry in the Neuroscience group of GlaxoSmithKline. During this time, he led many successful drug discovery programmes and delivered numerous development candidates.
In 2009 Paul left GSK to join Almirall in Barcelona, leading a department focused on the discovery of drugs to treat respiratory diseases by the inhaled route.
In 2013 Paul returned to the UK and joined the newly formed drug discovery group at the University of Sussex, where his role was to identify collaborations and secure research funding for the group. His work resulted in the sourcing of £12M funding and collaborations with both academic and industrial partners.
During this time Paul began consulting for biotechnology companies and academic researchers which he continues to do today.

LinkedIn
+

José Luis Fábregas

Consulting team

PhD in Chemistry (Autonomous University of Barcelona). Further a more than four decades-long…

PhD in Chemistry (Autonomous University of Barcelona). Further a more than four decades-long career in CMC top scientific and managerial functions in Almirall, S.A., which is the largest research-based pharmaceutical company in Spain and first Spanish pharmaceutical multinational firm, in last eleven years he focused on specific CMC consultancy for pharma and biotech companies in Spain and abroad. In his whole professional tenure, he has been responsible for getting a large number of products authorized by HHAA then marketed in true global basis, hence fulfilling both regulatory and GMP international CMC requirements. He has extensively lectured, and authored and coauthored in this field (50+ peer reviewed papers and communications) and owns 12 patents.

LinkedIn
+

Jesús Llenas

Consulting team

Jesús Llenas has a PhD in biology from the Autonomous University of Barcelona (UAB)…

Jesús Llenas has a PhD in biology from the Autonomous University of Barcelona (UAB). From his initial stay at Boehringer Ingelheim in 1975, he has dedicated his career to pharmaceutical development and has worked in investigative laboratories of technical and applied research in Barcelona. He worked for Almirall for more than 30 years and retired in 2009 from his post as manager of the pharmacology department. Dr. Llenas is secretary of the Spanish Society of Pharmacology and a member of the editorial board of the British Journal of Pharmacology, and since 2009 he has been a member of the Royal Academy of Pharmacy of Catalonia.

He is the author or co-author of more than 50 articles published in international journals and holds 10 patents. At present he is a consultant for various biotechnology companies. He is a consultant for Landsteiner Gemmed, where he coordinates studies in pre-clinical research.

LinkedIn
+

Agustín Ruiz

Scientific advisory board

Dr. Agustín Ruíz has a degree in medicine and surgery and also a PhD in molecular…

Dr. Agustín Ruíz has a degree in medicine and surgery and also a PhD in molecular and cellular biology from the University of Seville, for which he received mention as summa cum laude. He has had 192 articles published in indexed journals and has been involved in 7 patents related to molecular diagnostics in complex illnesses and bioinformatic tools in genomic research. He is a reviewer for the European Commission and is currently the manager of investigation and the scientific manager of ACE Foundation—the Catalan Institute of Applied Neuroscience in Barcelona (Alzheimer Treatment & Research Center).

LinkedIn
+

Santos Mañes

Scientific advisory board

Prof. Santos Mañes has a degree in biology sciences from the Complutense University of Madrid…

Prof. Santos Mañes has a degree in biology sciences from the Complutense University of Madrid (UCM) and a PhD in cellular and molecular biology from the Automonous University of Madrid (UAM). He has received many awards such as Investigator 13 and in particular an award for experimental biology and medicine from Maywood, New Jersey in the USA. He has been published more than 60 times in journals. He holds 4 patents and he is a frequent peer reviewer for journals such as Nature, Nature Reviews in Immunology, Immunity, and Journal of Clinical Investigation, among others. He has been a team leader for several pharmaceutical companies, such as Pharmacia and Pfizer. At present he works as a teacher of investigation at the Spanish National Research Council (CSIC) and leads a research group at the Department of Immunology and Oncology of the National Center of Biotechnology (CNB-CSIC) in Madrid, Spain.

LinkedIn
+

Luis Miguel Real

Scientific advisory board

Dr. Real has a PhD in biological sciences from the University of Granada and is a…

Dr. Real has a PhD in biological sciences from the University of Granada and is a specialist in immunology. He did his internship at the clinical analysis and immunology service of the Virgin del Rocio University Hospital in Seville for two years. He later founded and occupied managerial posts in the biotechnological company Neocodex S.L. He has had more than 100 articles published in indexed journals and holds 6 patents. He has participated in 16 projects that were financed following competitive calls and he was the chief investigator in 7 of them. Dr. Real is presently the manager of the investigation laboratory at the University Hospital of Valme in Seville, and he is a professor in the area of surgical, biochemical and immunological specializations at the Faculty of Medicine of the University of Malaga.

LinkedIn
+

Mª Eugenia Sáez

Scientific advisory board

Dr. Sáez has a degree in pharmacy and a PhD in molecular and cellular biology…

Dr. Sáez has a degree in pharmacy and a PhD in molecular and cellular biology from the University of Seville. She co-founded the company CAEBi which specializes in bioinformatic analysis, and this is where she currently works. Prior to this she worked as an investigator in the medical genetics unit at the Virgin del Rocio Hospital in Seville. She was also in charge of the cardiovascular department at the company Neocodex.  Dr. Sáez has wide-ranging experience in the analysis of genomic data in studies carried out in large population groups and in the use of biological system tools applied in various cardiovascular and metabolic pathologies, cancer, and Alzheimer. She has authored 60 articles published in international journals, holds 5 national and international patents in the field of molecular diagnosis, and has led a number of national and international projects (IMI, CENIT, Fondo Tecnológico, FP7, et al.).

LinkedIn
+

If you want more information about our studies

Ask us